WATERS CORPORATION

NYSE: WAT (Waters Corporation)

Last update: 4 hours ago

289.16

-11.40 (-3.79%)

Previous Close 300.56
Open 300.31
Volume 644,394
Avg. Volume (3M) 1,049,677
Market Cap 28,367,136,768
Price / Earnings (TTM) 26.87
Price / Earnings (Forward) 20.79
Price / Sales 5.64
Price / Book 11.45
52 Weeks Range
275.05 (-4%) — 414.15 (43%)
Earnings Date 5 May 2026
Profit Margin 22.02%
Operating Margin (TTM) 22.93%
Diluted EPS (TTM) 11.01
Quarterly Revenue Growth (YOY) 3.90%
Quarterly Earnings Growth (YOY) 18.80%
Total Debt/Equity (MRQ) 78.58%
Current Ratio (MRQ) 1.81
Operating Cash Flow (TTM) 758.81 M
Levered Free Cash Flow (TTM) 588.83 M
Return on Assets (TTM) 11.61%
Return on Equity (TTM) 40.82%

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Bullish
Diagnostics & Research (Global) Mixed Bullish
Stock Waters Corporation Bearish Bearish

AIStockmoo Score

2.2
Analyst Consensus 3.0
Insider Activity 3.0
Price Volatility 3.5
Technical Moving Averages 3.5
Technical Oscillators -2.0
Average 2.20

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
WAT 28 B - 26.87 11.45
A 32 B 0.22% 25.07 4.55
IQV 28 B - 20.90 4.29
MTD 26 B - 30.09 -
DHR 136 B 0.17% 38.14 2.55
TMO 178 B 0.09% 26.95 3.27

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Mid Core
% Held by Insiders 0.16%
% Held by Institutions 98.23%
52 Weeks Range
275.05 (-4%) — 414.15 (43%)
Price Target Range
350.00 (21%) — 460.00 (59%)
High 460.00 (HSBC, 59.08%) Buy
Median 370.00 (27.96%)
Low 350.00 (Morgan Stanley, 21.04%) Hold
350.00 (B of A Securities, 21.04%) Hold
Average 389.29 (34.63%)
Total 3 Buy, 4 Hold
Avg. Price @ Call 336.76
Firm Date Target Price Call Price @ Call
Morgan Stanley 23 Feb 2026 350.00 (21.04%) Hold 327.78
Barclays 11 Feb 2026 400.00 (38.33%) Buy 329.20
Wells Fargo 11 Feb 2026 355.00 (22.77%) Hold 329.20
B of A Securities 10 Feb 2026 350.00 (21.04%) Hold 327.02
Guggenheim 10 Feb 2026 440.00 (52.16%) Buy 327.02
UBS 10 Feb 2026 370.00 (27.96%) Hold 327.02
HSBC 27 Jan 2026 460.00 (59.08%) Buy 390.09
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
JIANG WEI 290.02 - 500 145,010
Aggregate Net Quantity 500
Aggregate Net Value ($) 145,010
Aggregate Avg. Buy ($) 290.02
Aggregate Avg. Sell ($) -
Name Holder Date Type Quantity Price Value ($)
JIANG WEI Director 16 Mar 2026 Buy (+) 500 290.02 145,010

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria